Financial Post EN

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy Salanersen is a novel antisense oligonucleotide and has the potential to deliver high efficacy in SMA with once-yearly dosing Biogen also debuted […]

Mar 11, 2026 &03061111202631; 12:06 UTC financialpost.com Trending 4/5

Read original on financialpost.com ↗

↗

Positive for markets

Sentiment score: +75/100

High impact Medium-term (weeks)

WHAT THIS MEANS

Biogen announced positive Phase 1b data for salanersen, demonstrating safety and efficacy over one year in SMA children previously treated with gene therapy, with potential for once-yearly dosing. This represents a significant advancement in treating spinal muscular atrophy and could expand Biogen's therapeutic portfolio in rare genetic diseases.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

BIIB

BIIBStock

Expected to rise

Positive clinical trial data for salanersen in SMA treatment supports pipeline strength and potential revenue growth from rare disease indication

↑

S&P 500

^GSPCIndex

Expected to rise

Biotech sector strength from positive rare disease therapeutic advancement

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider accumulating BIIB on any weakness as positive clinical data de-risks the salanersen program. Monitor for upcoming regulatory pathway announcements and Phase 2 trial initiation timelines for potential catalysts.

KEY SIGNALS

Positive Phase 1b clinical dataSafety and efficacy demonstrated over 12 monthsOnce-yearly dosing potential (improved patient compliance)Addresses unmet need in SMA treatmentExpansion of gene therapy follow-up options

SECTORS INVOLVED

BiotechnologyPharmaceuticalsHealthcare

Analysis generated on Mar 12, 2026 at 01:32 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Financial Post. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

RELATED INTELLIGENCE